Whittaker Dominic G, Ni Haibo, El Harchi Aziza, Hancox Jules C, Zhang Henggui
Biological Physics Group, School of Physics & Astronomy, The University of Manchester, Manchester, United Kingdom.
Department of Physiology, Pharmacology and Neuroscience, and Cardiovascular Research Laboratories, School of Medical Sciences, University of Bristol, Bristol, United Kingdom.
PLoS Comput Biol. 2017 Jun 13;13(6):e1005593. doi: 10.1371/journal.pcbi.1005593. eCollection 2017 Jun.
Gain-of-function mutations in KCNJ2-encoded Kir2.1 channels underlie variant 3 (SQT3) of the short QT syndrome, which is associated with atrial fibrillation (AF). Using biophysically-detailed human atria computer models, this study investigated the mechanistic link between SQT3 mutations and atrial arrhythmogenesis, and potential ion channel targets for treatment of SQT3. A contemporary model of the human atrial action potential (AP) was modified to recapitulate functional changes in IK1 due to heterozygous and homozygous forms of the D172N and E299V Kir2.1 mutations. Wild-type (WT) and mutant formulations were incorporated into multi-scale homogeneous and heterogeneous tissue models. Effects of mutations on AP duration (APD), conduction velocity (CV), effective refractory period (ERP), tissue excitation threshold and their rate-dependence, as well as the wavelength of re-entry (WL) were quantified. The D172N and E299V Kir2.1 mutations produced distinct effects on IK1 and APD shortening. Both mutations decreased WL for re-entry through a reduction in ERP and CV. Stability of re-entrant excitation waves in 2D and 3D tissue models was mediated by changes to tissue excitability and dispersion of APD in mutation conditions. Combined block of IK1 and IKr was effective in terminating re-entry associated with heterozygous D172N conditions, whereas IKr block alone may be a safer alternative for the E299V mutation. Combined inhibition of IKr and IKur produced a synergistic anti-arrhythmic effect in both forms of SQT3. In conclusion, this study provides mechanistic insights into atrial proarrhythmia with SQT3 Kir2.1 mutations and highlights possible pharmacological strategies for management of SQT3-linked AF.
KCNJ2 编码的 Kir2.1 通道功能获得性突变是短 QT 综合征 3 型(SQT3)的基础,该综合征与心房颤动(AF)相关。本研究使用具有生物物理细节的人体心房计算机模型,探究了 SQT3 突变与心房心律失常发生之间的机制联系,以及治疗 SQT3 的潜在离子通道靶点。对当代人体心房动作电位(AP)模型进行修改,以重现由于 D172N 和 E299V Kir2.1 突变的杂合和纯合形式导致的 IK1 功能变化。将野生型(WT)和突变体公式纳入多尺度均匀和异质组织模型。量化了突变对动作电位持续时间(APD)、传导速度(CV)、有效不应期(ERP)、组织兴奋阈值及其频率依赖性以及折返波长(WL)的影响。D172N 和 E299V Kir2.1 突变对 IK1 和 APD 缩短产生了不同影响。两种突变均通过降低 ERP 和 CV 来缩短折返的 WL。二维和三维组织模型中折返兴奋波的稳定性是由突变条件下组织兴奋性的变化和 APD 的离散介导的。联合阻断 IKI 和 IKr 可有效终止与杂合 D172N 条件相关的折返,而单独阻断 IKr 可能是 E299V 突变更安全的选择。联合抑制 IKr 和 IKur 在两种形式的 SQT3 中均产生协同抗心律失常作用。总之,本研究提供了对 SQT3 Kir2.1 突变所致心房心律失常机制的见解,并突出了治疗 SQT3 相关 AF 的可能药物策略。